STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.

Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.

Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.

Rhea-AI Summary

Amgen (NASDAQ:AMGN) has awarded a $25,000 grant to the Bath Institute of Rheumatic Diseases (BIRD) as part of the UPLIFT Innovation Challenge. This initiative aims to improve solutions for those living with psoriatic disease. BIRD's project focuses on connecting patients and healthcare providers through digital platforms, enhancing understanding and communication. Additionally, four other organizations received honorable mentions, each receiving a $20,000 grant. The challenge emerged from findings of the 2020 UPLIFT survey, highlighting gaps in care for psoriatic disease patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ: AMGN) announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending conditional marketing authorization for LUMYKRAS® (sotorasib) to treat adults with advanced non-small-cell lung cancer (NSCLC) harboring the KRAS G12C mutation. This marks a significant step towards the first targeted therapy for this mutation in the EU. The decision is based on the Phase 2 CodeBreaK 100 clinical trial, which showed a 37.1% objective response rate and 12.5 months median overall survival. A decision from the European Commission is expected by mid-January 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

Amgen will present at the 2021 Cowen IO Summit on November 15 at 2:15 p.m. ET. Dr. David M. Reese, Executive VP of Research and Development, will lead the presentation. The event will be accessible via live audio webcast for media, investors, and the public on Amgen's website. An archived version will be available for 90 days post-event. Amgen is recognized for its innovative biotechnological approaches to serious illnesses, leveraging human genetics to enhance health outcomes for millions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
Rhea-AI Summary

Amgen announced positive results from the HER-MES study, the first head-to-head trial comparing Aimovig® (erenumab-aooe) to topiramate for migraine prevention. The study demonstrated a significantly lower discontinuation rate due to adverse events (10.6% for Aimovig vs. 38.9% for topiramate) and superior efficacy, with 55.4% of Aimovig patients achieving at least a 50% reduction in monthly migraine days. The findings, published in Cephalalgia, strengthen Aimovig's profile as a migraine treatment, highlighting its potential for wider adoption among patients suffering from this debilitating condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Amgen has initiated construction of a new biomanufacturing plant in New Albany, Ohio, with an investment of $365 million, set to become operational by 2024. This facility will create approximately 400 jobs and aims to meet increasing demand for Amgen's medicines in the U.S. The plant is designed to be the company's most efficient and sustainable, with plans for LEED certification. Additionally, Amgen has received accolades for workplace diversity and aims to hire a million Black Americans in the next decade. This expansion marks a significant move for Amgen in maintaining its leadership in biologics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
Rhea-AI Summary

Amgen (AMGN) reported Q3 2021 revenues of $6.7 billion, marking a 4% year-on-year increase, driven by strong unit demand. GAAP EPS fell 3% to $3.31 due to a $400 million licensing expense, while non-GAAP EPS rose 11% to $4.67. The company generated $2.2 billion in free cash flow but this was a decline from $3.2 billion in Q3 2020. Amgen maintained its full-year revenue guidance between $25.8 billion and $26.2 billion, with GAAP EPS projected at $9.55-$10.21. New product LUMAKRAS showed promising sales, and a robust pipeline is expected to drive long-term growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
Rhea-AI Summary

Amgen will release its third quarter financial results on November 2, 2021, after market close. The announcement will be followed by a conference call at 2:00 p.m. PT, featuring CEO Robert A. Bradway and senior management. The call can be accessed via live audio on Amgen's website. This session aims to engage with the investment community, providing insights into the company's performance and future direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has declared a $1.76 per share dividend for Q4 2021, with payment scheduled for December 8, 2021. The record date for stockholders is November 16, 2021. This dividend reflects Amgen's commitment to returning value to its shareholders while addressing the significant unmet medical needs through its innovative therapies. As a leading biotechnology company since 1980, Amgen aims to improve health outcomes by leveraging advanced human genetics to develop effective therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
dividends
Rhea-AI Summary

Amgen has finalized its acquisition of Teneobio for a total of $900 million in cash, with potential future payments reaching up to $1.6 billion. This strategic move enhances Amgen's capabilities in developing bispecific and multispecific biologics, particularly for treating diseases like metastatic castrate-resistant prostate cancer. The acquisition includes Teneobio's proprietary technologies and investigational therapies, such as TNB-585, expected to accelerate Amgen’s oncology pipeline. Amgen aims to leverage these assets to address critical unmet medical needs in its therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

148.96B
536.44M
0.22%
82.06%
3.01%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS